705 - Ovarian Cancer: Drugs (Answered)

Mrs Sharon Hodgson
To ask the Secretary of State for Health, what steps his Department is taking to offer personalised medicines to women with BRCA-mutated ovarian cancer with limited treatment options.

George Freeman

NHS England provides BRCA testing services for women at high risk of breast and ovarian cancer.

Following the National Institute for Health and Care Excellence’s (NICE) updated clinical guideline on familial breast cancer published in June 2013, NHS England is currently considering whether to widen its offer of testing. NICE is also consulting on its draft technology appraisal guidance on the use of the new PARP inhibiter, olaparib (Lynparza) which is targeted at BRCA positive ovarian cancer. In addition, through initiatives like the 100,000 Genomes Project we will in time provide more insights into personalised treatments for ovarian cancer.